NCT03176654 (HVLAT) is a NA clinical trial of HVLAT manipulation in Neck Pain, Posterior, sponsored by Loma Linda University.

Who is sponsoring NCT03176654?

NCT03176654 is sponsored by Loma Linda University.

What drugs are being tested in NCT03176654?

Interventions in NCT03176654: HVLAT manipulation, Sham HVLAT manipulation.

What condition does NCT03176654 study?

NCT03176654 studies Neck Pain, Posterior.

Is NCT03176654 still recruiting?

NCT03176654 is currently completed. Last updated 1 August 2019.

Are results published for NCT03176654?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-08-01 · How we verify

NCT03176654: HVLAT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Manipulation of the Cervical Spine on Pain Biomarkers

Completed NA Results posted Last updated 1 August 2019

What this trial tests

NA trial testing HVLAT manipulation in Neck Pain, Posterior in 28 participants. Completed in 20 September 2016.

Timeline

15 August 2016

Primary endpoint
20 September 2016

20 September 2016

Quick facts

Lead sponsor	Loma Linda University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	basic science
Enrollment	28
Start date	15 August 2016
Primary completion	20 September 2016
Estimated completion	20 September 2016
Sites	1 location across United States

Drugs / interventions tested

HVLAT manipulation
Sham HVLAT manipulation

Conditions studied

Neck Pain, Posterior — all drugs for Neck Pain, Posterior →

Sponsor

Loma Linda University

Who can join

Adults 20 to 45, female only, with Neck Pain, Posterior. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Plasma Concentration of Oxytocin Primary · Blood will be drawn 10 minutes prior to HVLAT procedure.

Samples were analyzed for Human Oxytocin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Group	Value	95% CI
HVLAT Manipulation	154.5	± 0.9
Sham HVLAT Manipulation	158.8	± 0.5

Plasma Concentration of Oxytocin Primary · Blood will be drawn immediately after HVLAT procedure.

Samples were analyzed for Human Oxytocin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Group	Value	95% CI
HVLAT Manipulation	185.1	± 0.9
Sham HVLAT Manipulation	189.1	± 0.5

Plasma Concentration of Neurotensin Secondary · Within 10 minutes after consent signature completion

Samples were analyzed for Human Neurotensin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Group	Value	95% CI
HVLAT Manipulation	116.0	± 1.6
Sham HVLAT Manipulation	125.6	± 0.2

Plasma Concentration of Neurotensin Secondary · Blood will be drawn immediately after HVLAT procedure.

Samples were analyzed for Human Neurotensin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Group	Value	95% CI
HVLAT Manipulation	136.4	± 1.6
Sham HVLAT Manipulation	131.6	± 0.2

Plasma Concentration of Orexin A Secondary · Within 10 minutes after consent signature completion

Samples were analyzed for Human Orexin A, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Group	Value	95% CI
HVLAT Manipulation	52.2	± 1.0
Sham HVLAT Manipulation	62.9	± 0.2

Plasma Concentration of Orexin A Secondary · Blood will be drawn immediately after HVLAT procedure.

Samples were analyzed for Human Orexin A, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Group	Value	95% CI
HVLAT Manipulation	73.8	± 1.0
Sham HVLAT Manipulation	67.3	± 0.2

Plasma Concentration of Cortisol Secondary · Within 10 minutes after consent signature completion

Samples were analyzed for Human Cortisol, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Group	Value	95% CI
HVLAT Manipulation	95.8	± 0.8
Sham HVLAT Manipulation	127.4	± 0.5

Plasma Concentration of Cortisol Secondary · Blood will be drawn immediately after HVLAT procedure.

Samples were analyzed for Human Cortisol, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Group	Value	95% CI
HVLAT Manipulation	108.1	± 0.8
Sham HVLAT Manipulation	139.7	± 0.5

Sponsor's own description

This study evaluates the effect of high-velocity low-amplitude thrust (HVLAT) manipulation to the cervical spine on neuropeptide expression as determined by the plasma concentration of oxytocin, neurotensin, orexin A and cortisol; and Examine the effect of HVLAT manipulation on pain perception in symptomatic females with non-specific mechanical cervical spine pain

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Neck Pain, Posterior

Currently open trials in the same condition.

NCT05617365 — Treating Chronic Cervicogenic Head and Neck Pain · Phase 1, PHASE2 · recruiting

Other Loma Linda University trials

Trials by the same sponsor.

NCT07213843 — Combined Circulatory and Dietary Interventions for Neuropathy · NA · not yet recruiting
NCT07130812 — Blood Flow Restriction Training as a Targeted Intervention for Rowers With Back Pain. · NA · recruiting
NCT06673342 — Effectiveness of a Nutritional Counseling Tool in Reducing the Amount and Frequency of Sugar Intake · NA · completed
NCT06445842 — Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women · NA · recruiting
NCT07396831 — Necessity of Post-operative Eye Drops · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03176654 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Loma Linda University
Last refreshed: 1 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03176654.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing